-

Monsanto Wins Third Circuit Court of Appeals Ruling in Schaffner v. Monsanto

Decision presents pathway to take preemption argument to U.S. Supreme Court

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, the Third Circuit Court of Appeals issued its ruling in Monsanto’s favor in the Schaffner v. Monsanto case, unanimously finding that the state-based failure-to-warn claims in this case are expressly preempted by the FIFRA statute.

This decision creates a circuit split with prior decisions of the Ninth and Eleventh Circuits on the central legal issues in the Roundup litigation and underscores the need for consistency on this important topic from a federal standpoint.

In response to the Schaffner v. Monsanto ruling, Monsanto issued the following statement:

“The Company is pleased with the unanimous decision from the Third Circuit holding that plaintiff’s state-based warning claims are expressly preempted by FIFRA. The Court concluded that ‘the alleged state-law duty to include the Cancer Warning on Roundup’s label imposes requirements that are different from those imposed under FIFRA, and that it is therefore preempted by FIFRA.”

“This decision on federal preemption, a cross-cutting issue in this litigation, creates a circuit split among the federal appellate courts and necessitates a review by the U.S. Supreme Court to settle this important issue of law. The Company is considering the impact of this ruling on other pending litigation and looks forward to presenting its arguments, as fully embraced by the Third Circuit, to the U.S. Supreme Court.”

“Bayer continues to stand fully behind its Roundup™ products – critical tools that farmers rely on to produce affordable food and feed the world – as the weight of scientific evidence and the conclusions of expert regulators worldwide continue to support the safety of glyphosate-based herbicides and that they are not carcinogenic.”

Contacts

Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Monsanto


Release Versions

Contacts

Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Monsanto

One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin

WHIPPANY, N.J.--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand from Bayer, today announced a new formula for One A Day® Women's Multi Gummy, which now delivers 1,000 mcg of Biotin per serving (serving size is two gummies). The new formulation contains more biotin† with 2833% Daily Value (DV) than other leading multivitamin gummies including Olly Women’s Multi, Nature Made Women's Advanced Multivitamin Gummies, and Vitafusion Women's Multi (1000 mcg vs 150 mcg), while continu...

New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters

LEVERKUSEN, Germany--(BUSINESS WIRE)--Self-care, when effectively integrated into health systems, can improve health outcomes, expand access to healthcare services and reduce pressure on overstretched health systems, according to new research by Economist Enterprise. The research, supported by Bayer and published in a report titled “Making self-care work: integrating self-care into health systems”, cites existing evidence estimating that self-care practices can deliver approximately US$ 179 bil...

Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials

DETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer’s global drug development expertise with Henry Ford Health’s comprehensive clinical research program and its deep connection to the communities it serves. “Clinical trials are often the first opportunity patients have to access cutting-edge treatments,” said Dr. David Lanfear, Chief Scie...
Back to Newsroom